Annovis Bio Inc. Common Stock (ANVS)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that can earn real money and whose price leaves a margin of safety. Annovis Bio, at $1.06 as of the close on 2026-10-13, is a clinical-stage biotech with no reported revenue and a 7-person workforce. It has lost money in each of the last four years: in fiscal year 2023, the year ended 2023-12-31, net income was -$56.2M; in fiscal year 2024, the year ended 2024-12-31, net income was -$24.6M; and in fiscal year 2025, the year ended 2025-12-31, net income was -$28.9M. The recent quarters remain heavy: in fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$17.6M, and in fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$14.8M. Trailing free cash flow is -$43.3M, and the FairStock FCF yield is -96.0%. The market cap is $45.2M, so the company burns a large fraction of its equity value. FairStock ratios at that close show P/B of 16.82, ROE of -703.68%, ROCE of -142.36%, a Piotroski F-Score of 1/9, and an Altman Z-Score of -10.58. The FairStock Score is 22/100. The Lynch category is none because losses occurred in each of the last four years. The pipeline—Buntanetap in phase 3 for Alzheimer's and open-label phase 3 for Parkinson's, plus earlier candidates—offers binary hope, but I cannot identify a durable competitive moat from these figures. This is speculation on clinical outcomes, not a proven business, and the price is high versus the absence of earnings.

In plain English: Annovis Bio is a very small clinical-stage biotech that is testing drugs for Alzheimer's, Parkinson's, and other brain conditions. It has no reported revenue and has lost money in each of the last four years, including a $28.9 million loss in fiscal year 2025. The stock price is very low compared with a year ago, but because there are no profits and cash is being spent quickly, the price looks expensive relative to the financial numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer